LaBrosse Nicole's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Sep 23, 2025
- Accession no.
- 0001910662-25-000003
- Filed
- Sep 23, 2025
- Trade date
- Sep 22, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $173.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LaBrosse NicoleCIK 0001910662 | Officer (SVP, CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2025 | Common Stock | SSaleDisposed | −1,913 | $77.83 | −$148,888.79 | 22,393 | Direct | |
| Sep 22, 2025 | Common Stock | SSaleDisposed | −314 | $78.67 | −$24,702.38 | 22,079 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.